Shanghai Pharmaceuticals Holding Past Earnings Performance
Past criteria checks 2/6
Shanghai Pharmaceuticals Holding has been growing earnings at an average annual rate of 4.7%, while the Healthcare industry saw earnings growing at 4.4% annually. Revenues have been growing at an average rate of 9.1% per year. Shanghai Pharmaceuticals Holding's return on equity is 6.4%, and it has net margins of 1.4%.
Key information
4.7%
Earnings growth rate
-0.6%
EPS growth rate
| Healthcare Industry Growth | 15.7% |
| Revenue growth rate | 9.1% |
| Return on equity | 6.4% |
| Net Margin | 1.4% |
| Next Earnings Update | 26 Apr 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shanghai Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 260,295 | 3,768 | 19,768 | 2,204 |
| 30 Sep 23 | 254,878 | 4,600 | 20,060 | 2,191 |
| 30 Jun 23 | 252,866 | 4,531 | 20,906 | 2,329 |
| 31 Mar 23 | 241,310 | 5,884 | 20,229 | 2,205 |
| 31 Dec 22 | 231,981 | 5,617 | 19,447 | 2,112 |
| 30 Sep 22 | 229,463 | 5,423 | 18,587 | 2,010 |
| 30 Jun 22 | 222,294 | 5,221 | 18,802 | 1,917 |
| 31 Mar 22 | 221,122 | 4,224 | 18,403 | 2,020 |
| 31 Dec 21 | 215,824 | 5,093 | 18,321 | 1,987 |
| 30 Sep 21 | 212,559 | 5,378 | 17,691 | 1,983 |
| 30 Jun 21 | 209,982 | 5,621 | 17,082 | 1,860 |
| 31 Mar 21 | 203,061 | 5,578 | 17,033 | 1,730 |
| 31 Dec 20 | 191,909 | 4,496 | 16,712 | 1,657 |
| 30 Sep 20 | 186,271 | 4,284 | 17,250 | 1,530 |
| 30 Jun 20 | 181,156 | 4,237 | 17,115 | 1,462 |
| 31 Mar 20 | 181,007 | 3,993 | 17,274 | 1,420 |
| 31 Dec 19 | 186,566 | 4,081 | 17,610 | 1,350 |
| 30 Sep 19 | 182,100 | 3,908 | 17,628 | 1,165 |
| 30 Jun 19 | 175,781 | 4,134 | 16,992 | 1,146 |
| 31 Mar 19 | 168,705 | 3,987 | 16,015 | 1,118 |
| 31 Dec 18 | 159,084 | 3,881 | 15,098 | 1,061 |
| 30 Sep 18 | 149,417 | 4,204 | 13,892 | 1,043 |
| 30 Jun 18 | 140,947 | 3,629 | 12,607 | 896 |
| 31 Mar 18 | 134,104 | 3,541 | 11,511 | 1,004 |
| 31 Dec 17 | 130,847 | 3,521 | 10,601 | 790 |
| 30 Sep 17 | 129,279 | 3,428 | 10,436 | 503 |
| 30 Jun 17 | 126,848 | 3,389 | 10,230 | 373 |
| 31 Mar 17 | 124,619 | 3,306 | 10,284 | 0 |
| 31 Dec 16 | 120,765 | 3,196 | 9,930 | 0 |
| 30 Sep 16 | 116,993 | 3,155 | 9,444 | 0 |
| 30 Jun 16 | 114,262 | 3,075 | 9,226 | 0 |
| 31 Mar 16 | 109,667 | 3,033 | 8,796 | 0 |
| 31 Dec 15 | 105,517 | 2,877 | 8,543 | 0 |
| 30 Sep 15 | 102,723 | 2,857 | 8,509 | 0 |
| 30 Jun 15 | 99,336 | 2,807 | 8,279 | 0 |
| 31 Mar 15 | 96,250 | 2,738 | 8,150 | 0 |
| 31 Dec 14 | 92,399 | 2,591 | 7,872 | 0 |
| 30 Sep 14 | 88,881 | 2,477 | 7,528 | 0 |
| 30 Jun 14 | 83,518 | 2,371 | 7,283 | 0 |
| 31 Mar 14 | 79,907 | 2,174 | 7,133 | 0 |
| 31 Dec 13 | 78,223 | 2,214 | 7,103 | 0 |
| 30 Sep 13 | 74,988 | 2,155 | 6,857 | 0 |
| 30 Jun 13 | 73,175 | 2,066 | 6,754 | 0 |
Quality Earnings: S1R has high quality earnings.
Growing Profit Margin: S1R's current net profit margins (1.4%) are lower than last year (2.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: S1R's earnings have grown by 4.7% per year over the past 5 years.
Accelerating Growth: S1R's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: S1R had negative earnings growth (-32.9%) over the past year, making it difficult to compare to the Healthcare industry average (-7.5%).
Return on Equity
High ROE: S1R's Return on Equity (6.4%) is considered low.